CPDC is committed to treating all people in a way that allows them to maintain their dignity and independence through integration and equal opportunity. We are committed to meeting the needs of people with disabilities in a timely manner, and will do so by preventing and removing barriers to accessibility and meeting accessibility requirements under the Accessibility for Ontarians with Disabilities Act, 2005.
CPDC will provide training to employees and other relevant persons. Training will be provided in a way that best suits the duties of these identified groups.
CPDC will take the following steps to ensure employees are provided with the training required to meet Ontario’s accessible laws by January 1, 2015:
CPDC is committed to meeting the communication needs of people with disabilities. We will ensure that proper consideration is provided to employees, customers, and candidates with regard to determining their information and communication needs. We will ensure that all publicly available information is accessible upon request.
Centre for Probe Development and Commercialization
1280 Main Street West, NRB-A316
Hamilton, ON L8S 4K1
Phone: 905 525-9140 x21112
Fax: 905 522-7776
CPDC commits to meeting Accessibility Standards for the Design of Public Spaces when building or making modifications to public spaces. We will notify the public of any service disruption, should they occur, and provide available alternatives.
CPDC supports the full inclusion of persons with disabilities as identified in Accessibility for Ontarians with Disabilities Act, 2005 (AODA). As such, all policies and procedures will be developed or updated so as to respect and promote the dignity and independence of persons with disabilities. As required, this plan will be reviewed and updated every 5 years.
Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.
Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.